Frank Sams-Dodd

Title: Frank Sams-Dodd: Innovator in Amyloid Beta Peptide Research

Introduction

Frank Sams-Dodd is an innovative inventor based in Biberach, Germany, who has made significant contributions to the field of medicine through his research on amyloid beta peptides. With a total of three patents to his name, his work focuses on developing methods to treat diseases associated with alterations in amyloid beta levels.

Latest Patents

One of Frank Sams-Dodd's latest patents is a method for treating diseases and conditions linked to an altered level of amyloid beta peptides. This invention includes a method for administering therapeutically effective amounts of new enolcarboxamide compounds to mammals. His work aims to address diseases where an increased level of amyloid beta peptide isoforms is present or where changes in the ratios of these isoforms can lead to plaque formation. The detailed formulas described in his patent play a crucial role in the treatment of these conditions.

Career Highlights

Sams-Dodd has worked with prominent organizations, including Boehringer Ingelheim International GmbH and Boehringer Ingelheim Vetmedica GmbH. His positions in these companies have equipped him with a robust understanding of pharmaceutical research and development, enabling him to contribute valuable innovations to the medical field.

Collaborations

Throughout his career, Frank has collaborated with notable colleagues, including Klaus Bornemann and Guenter Trummlitz. These partnerships have enriched his research endeavors and fostered collaboration towards creating effective solutions in treating amyloid beta-related conditions.

Conclusion

Frank Sams-Dodd continues to be a pivotal figure in his area of expertise, leveraging his knowledge and expertise to innovate health solutions. His patents and collaborations highlight a dedication to advancing medical treatments for conditions associated with amyloid beta peptides, making a significant impact in the scientific community.